urticaria
Conditions
Interventions
The intravenous administration of nafamostat mesilate (0.04 mg/kg/hr), followed by the oral administartion of camostat mesilate (600 mg/day)
Sponsors
Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with urticaria 1. Not less than 20 years old (no upper limit) 2. Whose quality of life (QOL) were severely impaired from insufficient efficacy of conventional treatments or their adverse effects 3. Written informed consent 4. Who can be hospitalized for the treatment and attend the hospital after discharge for a month
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women or women of child bearing potential not using contraception 2. Patients with diseases as follows. Liver disease, psychological illness, convulsive and other seizure, heart disease, hemoglobinopathy, hemophilia, uncontrolled diabetes, and autoimmune diseases. 3. Patients who use medications that influence the coagulation and fibrinolytic cascade. 4. Patients who were administered nafamostat mesilate and camostat mesilate with serious adverse events. 5. Patients in contraindication of nafamostat mesilate and camostat mesilate. 6. Others who the physician judges are not suitable as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urticarial symptom scores before and after medications | — |
Countries
Japan
Contacts
Public ContactYoshimi Matsuo
Hiroshima University Department of Dermatology
Outcome results
None listed